학술논문
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
Document Type
Article
Author
Barbour, T.; Scully, M.; Ariceta, G.; Cataland, S.; Garlo, K.; Heyne, N.; Luque, Y.; Menne, J.; Miyakawa, Y.; Yoon, S.-S.; Kavanagh, D.; Babu, S.; Broeders, N.; Lietar, N.; Brown, F.; Campbell, P.; Campistol, J.M.; Chowdhury, P.; Kasimatis, T.; Cirami, L.; Caroti, L.; Antognoli, G.; Delmas, Y.; Dobronravov, V.; Gaeckler, A.; Garrouste, C.; Greenwood, G.; Griffin, S.; Huang, C.-C.; Chen, I.-R.; Huang, S.; Kim, J.S.; La Manna, G.; Le Quintrec, M.; Jeantet, G.; Fumie, I.; Rondeau, E.; Haller, H.; Morelle, J.; Goffin, E.; Muhlfeld, A.; Nagaraj, S.; Arepally, G.; Oh, D.; Okumi, M.; Terente, M.P.; Provot, F.; Schönermarck, U.; Fischereder, M.; Terrada, N.R.; Seitz-Polski, B.; Favre, G.; Boyer-Suavet, S.; Vinogradova, M.; Kirsanova, T.; Wong, E.K.S.
Source
In: Kidney International Reports . (Kidney International Reports, June 2021, 6(6):1603-1613)
Subject
Language
English
ISSN
24680249